Large-scale Production & Purification Of Compounds With

大规模生产

• 批准号: 7334670
• 负责人: Joseph Shiloach
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7334670
• 关键词: Large; scale; Production; Purification; Compounds

The Biotechnology Unit is responsible for the production and purification of biological material. The Unit undertakes a wide array of biological production tasks such as large scale growth of prokaryotes and eucaryotes, and production and purification of biological compounds especially proteins. These products, not available from commercial sources, are needed for clinical and structural studies. The Biotechnology Unit is capable of handling these various production tasks by implementing both physiological and technical approaches. Efficient process development and production is possible since the Unit possesses two integrated elements: a fully operational multi purpose pilot production facility and the capability of conducting research and process development. During the last year the unit performed approximately 200 different, production preparations including: 1) growing various microorganisms such as recombinant Escherichia coli, recombinant Pichia pastoris, yeasts, mutant strain of Corynebacteria diphtheria and mutant strain of Bacillus anthracis; 2) propagating large volumes of mammalian cells such as HeLa, CHO, HEK 293, insects cells such as Sf 9 and hi five; 3) purifying gram quantities of recombinant Pseudomonas aeruginosa exotoxin A, protective antigen from Bacillus anthracis, Staphylococcal enterotoxin type C, recombinant malarial protein CSP, Chlostridium difficile toxin A, recombinant adiponectin and several antibodies from hybridoma cultures and rabbit serum. On the research and development arena, the unit conducted work in the following topics: 1) Continued the development of more efficient methods for large scale protein recovery, work was continued on the implementation of expanded bed adsorption techniques utilizing new types of expanded column: this column does not have flow adaptors and screens and therefore can handle larger concentration of biomass at higher low rates; 2) continued its research aimed at understanding the glucose metabolism of various recombinant E. coli strains in an effort to find out why certain strains are more suitable for foreign protein production using microarrays technology and protein analysis; 3) continued its research project associated with mammalian cells aiming at understanding the genetic difference between cells that can grow in suspension, and cells that are anchorage dependent. 4) In collaboration with LDMI, NICHD, the unit continued the work on the development of new vaccine against Shigella flexneri and Bacillus anthracis, the products are currently in clinical trials.5) the unit continued its research and development project on the production of recombinant proteins from filamentous fungi. 6) A new research and development project aiming at the production of plasmid DNA was initiated.

生物技术单元负责生物材料的生产和纯化。该单元执行了广泛的生物生产任务，例如大规模的原核生物和桉树的大规模增长，以及生物化合物尤其是蛋白质的生产和纯化。这些产品（无法从商业来源获得）进行临床和结构研究。生物技术部门能够通过实施生理和技术方法来处理这些各种生产任务。由于该单元具有两个综合元素，因此有效的过程开发和生产是可能的：一个完全运行的多用途试点生产设施以及进行研究和过程开发的能力。在过去的一年中，该单元进行了大约200种不同的生产制剂，包括：1）种植各种微生物，例如重组大肠杆菌，重组肉芽菌，帕斯托里斯，酵母，酵母，二甲状腺杆菌的突变菌株和芽孢杆菌的突变菌株； 2）传播大量的哺乳动物细胞，例如HeLa，Cho，Hek 293，昆虫细胞，例如SF 9和HI 5； 3）纯量铜毒素A铜毒素A，来自炭疽芽孢杆菌的保护性抗原，C型C型葡萄球菌肠毒素C型，重组疟疾蛋白CSP，CHLOSTRIDIUM艰难杆菌A A A，Recombinant腺苷和几种抗生素的再生血清素和几种抗生素和几种抗生素。在研发领域，该单元在以下主题中进行了工作：1）继续开发更有效的大规模蛋白质恢复方法，继续在实施扩展的床吸附技术的实施方面继续使用新型的扩展列：此列没有流动适配器和筛查，因此可以在更高的低率下处理更大的生物量浓度； 2）继续其研究旨在了解各种重组大肠杆菌菌株的葡萄糖代谢，以找出为什么使用微阵列技术和蛋白质分析的某些菌株更适合外国蛋白质生产； 3）继续其与哺乳动物细胞相关的研究项目，旨在了解悬浮液中可能生长的细胞与锚定依赖性细胞之间的遗传差异。 4）该单位与LDMI的合作，继续开发针对Shigella flexneri和炭疽芽孢杆菌的新疫苗开发的工作，这些产品目前正在临床试验中。5）该单元继续其研究和开发项目，研究和开发项目，从丝状真菌中生产重组蛋白。 6）启动了一个针对质粒DNA生产的新研究和开发项目。